This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): RXDX-101, RXDX101, NMS-E628, NMSE628
Description: RXDX-101 is a tyrosine kinase inhibitor of TrkA, TrkB, TrkC, ROS1, and ALK.
Nerviano and Ignyta
In November 2013, Nerviano signed a license agreement with Ignyta granting Ignyta excluse global development and marketing rights to RXDX-101 and RXDX-102. Under the terms of the license agreement, Ignyta will assume sole responsibility for global development and commercialization of RXDX-101 and RXDX-102. Nerviano will be entitled to receive certain upfront and milestone payments, as well as tiered royalty payments on future net sales of RXDX-101 or RXDX-102.
In December 2014, Ignyta announced that it has entered into an amendment to its license agreement with Nerviano relating to its entrectinib (formerly RXDX-101) product candidate. The amendment modifies the milestones that would trigger the initial three milestone payments specified in the license agreement. Pursuant to the amendment, the initial milestone payment of $10 million will be due and payable to Nerviano by December 31, 2014, and the second and third milestone payments will be...See full deal structure in Biomedtracker
Partners: Nerviano Medical Sciences
Additional information available to subscribers only: